Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4035 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Recruiting A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Clear-cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Kidney Diseases;   Kidney Neoplasms;   Metastatic Renal Cell Carcinoma
Intervention: Drug: CDX-014
22 Recruiting Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Squamous;   Squamous Cell Carcinoma;   Lung Neoplasms;   Cancer of Lung;   Cancer of the Lung;   Lung Cancer;   Neoplasms, Lung;   Neoplasms, Pulmonary;   Pulmonary Cancer;   Pulmonary Neoplasms
Intervention: Genetic: DNA Extraction
23 Recruiting Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Conditions: Colorectal Large Cell Neuroendocrine Carcinoma;   Esophageal Large Cell Neuroendocrine Carcinoma;   Gallbladder Large Cell Neuroendocrine Carcinoma;   Gastric Large Cell Neuroendocrine Carcinoma;   Pancreatic Large Cell Neuroendocrine Carcinoma;   Small Intestinal Large Cell Neuroendocrine Carcinoma
Interventions: Drug: Capecitabine;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
24 Recruiting A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Advanced Fibrolamellar Carcinoma
Intervention: Drug: ENMD-2076
25 Recruiting Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   HER2/Neu Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Head and Neck Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
26 Recruiting Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
27 Recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Neuroendocrine Carcinoma,;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
28 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
29 Recruiting TACE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatoma;   Liver Cancer, Adult;   Liver Cell Carcinoma;   Liver Cell Carcinoma, Adult
Interventions: Procedure: Transarterial Chemoembolization;   Procedure: Microwave Ablation
30 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
31 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
32 Recruiting Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat;   Drug: cisplatin;   Radiation: radiation therapy;   Procedure: Correlative Studies
33 Recruiting Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Cancer of Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck;   Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head and Neck
Interventions: Biological: MK-3475;   Procedure: Surgery;   Radiation: Intensity modulated radiation therapy;   Radiation: Image-guided radiation therapy;   Drug: Cisplatin
34 Unknown  TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Stage III Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma
Intervention: Drug: TPF induction chemotherapy
35 Recruiting Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Conditions: Fibrolamellar Hepatocellular Carcinoma;   Hepatocellular Carcinoma (Fibrolamellar Variant);   Hepatocellular Carcinoma
Interventions: Procedure: living related donor partial liver transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow transplant from same donor;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: mycophenolate mofetil;   Drug: Prednisone;   Drug: Antithymocyte globulin;   Drug: fludarabine
36 Recruiting Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
Conditions: Endometrial Carcinoma;   Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma;   Cervical Carcinoma
Interventions: Drug: AL3818;   Drug: Carboplatin;   Drug: Paclitaxel
37 Recruiting A Study of rSIFN-co in Subjects With Advanced Solid Tumors
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Melanoma;   Carcinoma, Hepatocellular;   Colon Cancer
Intervention: Drug: rSIFN-co
38 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
39 Not yet recruiting Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
Condition: Small Cell Carcinoma
Interventions: Drug: Nortriptyline Hydrochloride;   Drug: Paclitaxel
40 Unknown  Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Conditions: Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma
Intervention: Drug: Famitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years